Drug
BEA 2180 clinical trials
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2004 (2)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BEA 2180 is read from its arms, and is right about nine times in ten.
Testing it · 10
- An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.CompletedPhase 2Boehringer IngelheimNCT00528996Written as BEA 2180 BR
- Dose Finding Study in COPDCompletedPhase 2Boehringer IngelheimNCT00122434Written as BEA 2180 BR
- Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male SubjectsCompletedPhase 1Boehringer IngelheimNCT02263976Written as BEA 2180 BR
- Metabolism and Pharmacokinetics of [14C] BEA 2180 BR Administered Orally Compared to [14C] BEA 2180 BR Administered Intravenously in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02258971Written as BEA 2180 BR oral
- Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02254720Written as BEA 2180 BR solution for infusion
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02254122Written as BEA 2180 BR
- Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BEA 2180 BR in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02254135Written as BEA 2180 BR - rising dose
- Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02254109Written as BEA 2180 BR - rising dose
- Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD PatientsCompletedPhase 2Boehringer IngelheimNCT02242279Written as BEA 2180 BR
- High Dose Trial in COPDCompletedPhase 2Boehringer IngelheimNCT00128440Written as BEA 2180 BR